CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Oxaliplatin, Capecitabinedrug
Likely dose
Oxaliplatin, Capecitabine 85 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00266279
NCT00266279Phase 2Completed
CompareCT.gov

Phase II Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies

University of Louisville·interventional·Posted Dec 16, 2005·Updated Sep 3, 2020

In Brief

A Phase 2 clinical trial evaluating Oxaliplatin, Capecitabine for Head or Neck Cancer. Completed, enrolled 17 participants across 1 site.

Detailed Summary

This phase II study will test the response rate of combined oxaliplatin and capecitabine treatment when administered at a given dose and schedule, in patients with Head and Neck cancer for which there is no curative treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead or Neck Cancer
CountriesUnited States
CollaboratorsJames Graham Brown Cancer Center

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 16, 2005
Enrollment StartApr 1, 2005
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 20.5 years ago

Interventions

Oxaliplatin, Capecitabinedrug

Agent, DOSE AND SCHEDULE (28-days cycle): Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21